In the August issue of the journal, Freeman et al (Surgery 2000;128:281-5) described
an apparent association of cytochrome P450 (CYP) polymorphisms with reduced dosage
requirements for the anticoagulant warfarin. Pooled data from patients being either
heterozygous for the inactive CYP2A6*2 allele (2 subjects) or patients having mutations in the CYP2C9 gene (11 subjects) were compared with 25 patients with wild-type (normal) alleles.
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to SurgeryAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Human P450 metabolism of warfarin.Pharmacol Ther. 1997; 73: 67-74
- Association of polymorphisms in the cytochrome P450 CYP2C9 with warfarin dose requirement and risk of bleeding complications.Lancet. 1999; 353: 717-719
- Validation of methods for CYP2C9 genotyping: frequencies of mutant alleles in a Swedish population.Biochem Biophys Res Commun. 1999; 254: 628-631
- CYP2A6: a human coumarin 7-hydroxylase.Toxicology. 2000; 144: 139-147
- Human and mouse liver coumarin 7-hydroxylases do not metabolize warfarin in vitro.Br J Clin Pharmacol. 1992; 33: 313-317
- Hydroxylation of warfarin by human cDNA-expressed cytochrome P-450: a role for P-4502C9 in the etiology of (S)-warfarin-drug interactions.Chem Res Toxicol. 1992; 5: 54-59
Article info
Identification
Copyright
© 2001 Mosby, Inc. Published by Elsevier Inc. All rights reserved.
